ISTO Technologies Announces Participation in OneMedForum NY 2013
Jun 20, 2013
June 20, 2013 (St. Louis, MO) – ISTO Technologies, Inc. a state-of-the-art regenerative medicine company developing innovative cartilage and bone products for spinal therapy, sports medicine and other orthopedic indications, announced today that Scott Gill, Chief Financial Officer, is scheduled to present at OneMedPlace’s 4thAnnual OneMedForum NY 2013 conference to be held at the Metropolitan Club in New York City on June 27, 2013. Mr. Gill is scheduled to present at 2:40 PM (ET) in the Morgan Room. OneMedForum NY 2013 will focus on the new financing strategies made possible by the JOBS Act, with a showcase of investment opportunities in fast growing private (pre-IPO) companies and small cap public companies.
ISTO’s main strategic focus is on the development of its juvenile allogeneic cartilage technology platform for cartilage regeneration. In adults, injured cartilage does not normally heal or regenerate. ISTO has developed unique, proprietary methods to expand and preserve cartilage cells derived from juvenile cartilage tissue, which has exceptional regenerative potential when compared to adult cells. This allows the company to potentially offer a product with far superior healing and regenerative capabilities compared to competing technologies.
ISTO currently has two cartilage products in FDA-controlled human clinical trials targeting articular cartilage defects in the knee and degenerative spinal disc. RevaFlex™ is an off-the-shelf, scaffold-free engineered cartilage tissue implanted onto focal knee cartilage defects using a biologic glue. With over 5 years follow-up of a phase I/II clinical trial, RevaFlex has demonstrated safety as well as potential effectiveness in the early treatment for injured cartilage in the knee. RevaFlex is currently in a Phase III clinical trial, designed to demonstrate superiority over standard-of-care microfracture. The second cell-based product, NuQu®, is currently in a randomized Phase II clinical trial. The product was developed as a minimally-invasive therapeutic application of juvenile chondrocytes for the early treatment of patients with moderate to severe back pain, also known as discogenic back pain. This application targets patients who are non-responsive to conservative treatment (i.e., bed rest, physical therapy and local pharmacologic injections), and whose only alternative is a surgical procedure.
Finally, in addition to its cartilage platform technology, ISTO developed, patented and markets a unique biosynthetic for tissue regeneration. Although a potential platform for multiple uses, its initial target is for bone regeneration. InQu® is a novel biomaterial that combines the polymer PLGA and hyaluronic acid, offering a great scaffold with a unique biology not shared with other synthetic products currently in the market. To date, over 27,000 patients have been treated with InQu.
ISTO is a leading privately-held regenerative medicine company dedicated to improving patient quality of life through the development of proprietary products for spinal therapies and sports medicine applications. ISTO’s products are intended for the repair and regeneration of damaged or injured cartilage and bone. For additional information on ISTO, please visit our website at www.istobiologics.com.